108 Views | 57 Downloads
Correspondence: David A. Bond, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 1140A Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210; e-mail: david.bond@osumc.edu
Author contributions:D.A.B. and J.B.C. conceived and designed the study, collected and analyzed data, and wrote the manuscript; J.M.S. performed statistical analyses and wrote the manuscript;
D.V. collected and analyzed the data, performed the statistical analyses, and wrote the manuscript; K.M., M.C., A.S.G, S.G., K.S., O.C., B.K., V.B., J.N.G., S.K.B., B.T.H., Y.S., P.M., E.M., M.G., A.V.D., N.S.G., S.M., M.B., R.K., N.G., S.I.P., N.E., T.B., J.G., M.H., T.S.F., M.M., B.S.K, C.R.F., and K.A.B. collected and analyzed the data and wrote and reviewed the manuscript.
Disclosures: Conflict-of-interest disclosure: D.V. has received research funding from Roche and AstraZeneca and has consulted for Roche, Celgene, AbbVie, Seagen, Kite/Gilead, Lundbeck, Nanostring, AstraZeneca, Purdue Pharma, Sandoz, and Janssen. K.M. has received research funding from Bristol-Myers Squibb, Novartis, and Pharmacyclics and has consulted for ADC Therapeutics, AstraZeneca, Beigene, Bristol-Myers Squibb,
Celgene, Kite, Morphosys, and Seattle Genetics. A.S.G has received research funding from Roche Canada, Janssen, AbbVie, and AstraZeneca; has served on advisory boards for Janssen, AbbVie, AstraZeneca, and Sandoz; and has received honoraria from Janssen. V.B. has served on the advisory board for Gamida Cell Kite and has received research funding from Karyopharm, FATE, Bristol Myers Squibb, and Incyte.
J.N.G. has received research support from Loxo and has consulted for Genetech, AbbVie, and TG Therapeutics. S.K.B. has served on advisory boards for Seagen, Daiichi Sanko, and Atara and has consulted for Acrotech and Seagen.
A.V.D. has received research funding from Aptose Biosciences, AstraZeneca, Gilead Sciences, Takeda Oncology, Genentech, Bayer Oncology, Verastem Oncology, and Bristol-Myers Squibb and has consulted for AstraZeneca, Abbvie, Beigene, Bayer Oncology, Bristol-Meyers-Squibb, Genentech, Karyopharm, Pharmacyclics, TG Therapeutics, Nurix, and Rigel Pharmaceuticals.
N.S.G. has received research funding from Genetech and has consulted for Kite and Tessa Therapeutics. R.K. has received research funding from Kite/Gilead Sciences, Juno/Bristol-Meyers-Squibb, and Takeda Oncology and has served on advisory boards for Kite/Gilead Sciences, Juno/Bristol-Meyers-Squibb, Janssen, and Karyopharm and on the speakers bureau for AstraZeneca, Kite/Gilead Sciences, and BeiGene.
B.T.H. has received research funding from and has consulted for Genentech. P.M. has consulted for ADC Therapeutics, AstraZeneca, Bayer, Bristol Myers Squibb, Cellectar, Epizyme, Gilead, Incyte, Janssen, Karyopharm, Merck, Regeneron, Takeda, Teneobio, and Verastem; has received research funding from Celgene/Bristol Myers Squibb, Takeda, and Gilead/Kite; has consulted for Celgene/Bristol Myers Squibb, Karyopharm, and Gilead/Kite;
has served on the speaker’s bureau for Celgene/Bristol Myers Squibb, BeiGene, AstraZeneca, and Gilead/Kite. N.E. has served on the speaker’s bureau for Verastem and Beigene and has consulted for Karyopharm and Genzyme. M.H. has received research funding from Takeda, Spectrum Pharmaceuticals, and Astellas Pharma; has consulted for Janssen, Incyte, ADC Therapeutics, Celgene, Omeros, Verastem, and MorphoSys;
has served on the speaker’s bureau for Sanofi Genzyme, AstraZeneca, and BeiGene. T.S.F. has received research funding from Novartis, TG Therapeutics, Portola, and Curis; has consulted for Beigene, Genentech, Adaptive Biotechnologies, AbbVie, Verastem, Kite, MorphoSys, AstraZeneca, Pharmacyclics, and Sanofi; and has served on speaker boards for Genentech, Sanofi, Seattle Genetics,
AstraZeneca, Celgene/Bristol-Myers Squibb, and Adaptive Biotechnologies. C.R.F. has received research funding from Kite, Gilead, Celgene, AbbVie, Acerta, Karyopharm, Takeda, Roche, and TG Therapeutics and has consulted for Janssen/Pharmacyclics, Spectrum, Gilead/Kite, Celgene, AbbVie, Karyopharm, Bayer, Denovo Biopharma, Takeda, BeiGene, and Genentech.
J.B.C. has received research funding from Janssen, Adicet, AstraZeneca, Genentech, Cellectar, and Kite/Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, LAM, BioInvent, AstraZeneca, Seagen, and Loxo. The remaining authors declare no competing financial interests.
This work was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and the National Institutes of Health, National Cancer Institute (NIH/NCI; P30CA138292)
Center for Clinical and Translational Science Bioinformatics Shared Resource of The Ohio State University (UL1TR002733).
© 2021 by The American Society of Hematology.